Joshua Iszatt profile

Joshua Iszatt

Joshua is a second-year PhD candidate with an aim to investigate the potential of bacteriophage therapies for people who suffer from persistent bacterial infections. Cystic Fibrosis (CF) is a fatal genetic disorder in which individuals suffer from a cycle of persistent bacterial infection, followed by antibiotic treatment which results in antibiotic resistance later in life. His aims are as follows; to isolate and characterise a bacteriophage active against a range of resistant _Staphylococcus aureus _bacteria from CF airways and to provide data supporting the safety of using bacteriophage as an inhaled therapeutic for people with CF

Publication | September, 2021
Review paperRespiratory Tract infectionsPhage Therapy
Publication | November, 2021
Phage host rangePseudomonasScreening assayResearch paper
© 2024 Phage Australia